2026 Q1 -tulosraportti
60 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenExcerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1
It is perfect for the competitors. If it turns out that an interesting market can be cultivated, they can copy the FDA process without spending money on creating the initial interest and move in when the patents expire shortly.
·3 päivää sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026
Well, KDIGO has given the NGAL test different recommendations, and they have given the NGAL test the strongest recommendations on some topics, which I have previously informed about. I have inserted a link to KDIGO's recommendations. KDIGO has done it in such a way that there are 18 circles representing 18 different topics; these topics have each been given their own color. KDIGO has done it this way, to come up with the preliminary recommendations for the different topics, because it is Bioporto's test that KDIGO has used to arrive at these different recommendations, for if they only publish it when they are completely finished with the final documents (I have read somewhere that it will be more than 8000 pages), then KDIGO's committee may fear that bottlenecks will occur, because Bioporto naturally cannot deliver to the whole world at once, and also cannot manage to teach everyone and Validate etc. But if the departments wait to get the test integrated into their system, then they must also expect that bottlenecks will occur. It is only when the documents are completely finished that the different treatment centers should react based on the recommendations that KDIGO has given. The colors mean the following: The red one. it is the strongest recommendation. Here it will be mandatory for the departments that have received a red recommendation to have the NGAL test as part of their routine treatments. The blue one a moderate recommendation, meaning that it is not as strong a recommendation as red, but KDIGO urges that they have the NGAL test in their system The yellow one here it is optional for the department whether they want to use the NGAL test The green one no recommendation https://kdigo.org/guidelines/- ·3 päivää sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?
Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down, - ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
60 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenExcerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1It is perfect for the competitors. If it turns out that an interesting market can be cultivated, they can copy the FDA process without spending money on creating the initial interest and move in when the patents expire shortly.
- ·3 päivää sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026Well, KDIGO has given the NGAL test different recommendations, and they have given the NGAL test the strongest recommendations on some topics, which I have previously informed about. I have inserted a link to KDIGO's recommendations. KDIGO has done it in such a way that there are 18 circles representing 18 different topics; these topics have each been given their own color. KDIGO has done it this way, to come up with the preliminary recommendations for the different topics, because it is Bioporto's test that KDIGO has used to arrive at these different recommendations, for if they only publish it when they are completely finished with the final documents (I have read somewhere that it will be more than 8000 pages), then KDIGO's committee may fear that bottlenecks will occur, because Bioporto naturally cannot deliver to the whole world at once, and also cannot manage to teach everyone and Validate etc. But if the departments wait to get the test integrated into their system, then they must also expect that bottlenecks will occur. It is only when the documents are completely finished that the different treatment centers should react based on the recommendations that KDIGO has given. The colors mean the following: The red one. it is the strongest recommendation. Here it will be mandatory for the departments that have received a red recommendation to have the NGAL test as part of their routine treatments. The blue one a moderate recommendation, meaning that it is not as strong a recommendation as red, but KDIGO urges that they have the NGAL test in their system The yellow one here it is optional for the department whether they want to use the NGAL test The green one no recommendation https://kdigo.org/guidelines/
- ·3 päivää sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down,
- ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
60 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenExcerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1It is perfect for the competitors. If it turns out that an interesting market can be cultivated, they can copy the FDA process without spending money on creating the initial interest and move in when the patents expire shortly.
- ·3 päivää sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026Well, KDIGO has given the NGAL test different recommendations, and they have given the NGAL test the strongest recommendations on some topics, which I have previously informed about. I have inserted a link to KDIGO's recommendations. KDIGO has done it in such a way that there are 18 circles representing 18 different topics; these topics have each been given their own color. KDIGO has done it this way, to come up with the preliminary recommendations for the different topics, because it is Bioporto's test that KDIGO has used to arrive at these different recommendations, for if they only publish it when they are completely finished with the final documents (I have read somewhere that it will be more than 8000 pages), then KDIGO's committee may fear that bottlenecks will occur, because Bioporto naturally cannot deliver to the whole world at once, and also cannot manage to teach everyone and Validate etc. But if the departments wait to get the test integrated into their system, then they must also expect that bottlenecks will occur. It is only when the documents are completely finished that the different treatment centers should react based on the recommendations that KDIGO has given. The colors mean the following: The red one. it is the strongest recommendation. Here it will be mandatory for the departments that have received a red recommendation to have the NGAL test as part of their routine treatments. The blue one a moderate recommendation, meaning that it is not as strong a recommendation as red, but KDIGO urges that they have the NGAL test in their system The yellow one here it is optional for the department whether they want to use the NGAL test The green one no recommendation https://kdigo.org/guidelines/
- ·3 päivää sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down,
- ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt